Lipid accumulation in the subendothelial space, following deposition and retention of apolipoprotein B--containing plasma lipoproteins, is a key process in the initiation and progression of atherosclerosis [@bib1]. Studies of ex vivo tissue in coronary [@bib2] and carotid [@bib3] atherosclerosis have demonstrated that plaques associated with thrombotic complications tend to contain larger lipid-rich necrotic core (LRNC), among other high-risk features such as thin fibrous cap, infiltration of inflammatory cells, and the presence of intraplaque hemorrhage (IPH). Therefore, 1 of the key goals in risk-stratifying vulnerable plaques has become the identification and quantification of LRNC using in vivo vessel wall imaging [@bib4].

Although intensive lipid-lowering therapy can reduce total carotid vessel wall area [@bib5], direct evidence of lipid removal has been sparse [@bib6]. One particular challenge is that evacuated lipids tend to be replaced by fibrous tissue [@bib7], so that changes in total vessel wall area might be small or indiscernible by conventional imaging. As a new generation of lipid-lowering agents emerges [@bib8], [@bib9], tools for robust quantitative assessment of plaque composition may facilitate refinement and stratification for patient selection, and allow better monitoring of treatment response.

Multicontrast cardiovascular magnetic resonance (CMR) is an established technique in plaque characterization [@bib10]. However, optimal techniques for quantitative LRNC detection on multicontrast CMR require injection of contrast media [@bib6], [@bib11], and rely on tissue contrast relative to the adjacent sternocleidomastoid muscle, which depends on specific system and acquisition parameters. Moreover, multicontrast CMR suffers from blurring artifacts due to fast spin echo acquisitions [@bib12] and needs extensive post-processing to coregister different contrast-weighted images and correct for image intensity variations [@bib13].

We recently reported a quantitative CMR method to map T~2~ relaxation times of plaque components on a voxel-by-voxel basis [@bib14]. Compared to multicontrast CMR, this novel approach is more objective, as it requires minimal user interaction in the analysis, and calculates real quantitative information on plaque composition. This raises the important possibility of in vivo plaque lipid quantification, at high resolution, across the entire plaque, and without the use of gadolinium-based contrast. In addition, plaque T~2~ mapping addresses the need for an absolute physical parameter that can be standardized among different CMR systems and widely adopted in multicenter studies. Accordingly, here we sought: 1) to validate lipid quantification on carotid T~2~ maps using histology gold standard; and 2) to evaluate its potential clinical application in relation to identifying recently unstable plaques.

Methods {#sec1}
=======

Study population {#sec1.1}
----------------

Ethical approval was obtained from National Research Ethics Services and local R&D committee. Forty patients awaiting carotid endarterectomy at Oxford University Hospitals NHS Trust were recruited from November 2011 to June 2014. Patients were scanned at the Oxford Acute Vascular Imaging Centre ≤24 h before surgery. Carotid plaques were collected at operation. Patients either had recently symptomatic (median time from index event 2 weeks) or asymptomatic carotid disease, with 50% to 99% stenosis according to NASCET (North American Symptomatic Carotid Endarterectomy Trial), or 70% to 99% according to ESCT (European Carotid Surgery Trial) criteria. Plaques were defined as culprit plaques where they were deemed to have given rise to either a minor cerebrovascular accident or a transient ischemic attack as assessed clinically and supported, where available, by brain magnetic resonance imaging or computed tomography imaging. Asymptomatic carotid plaques were those that had no documented clinical symptoms, but with an indication for carotid endarterectomy on the basis of percent stenosis.

CMR protocol {#sec1.2}
------------

Patients were imaged on a Verio 3-T scanner (Siemens Healthcare, Erlangen, Germany) with a 4-channel phased-array carotid coil (Machnet, Roden, the Netherlands). Bright-blood time-of-flight (TOF) angiography of the carotid arteries was acquired to localize carotid bifurcation and lumen stenosis. Two-dimensional carotid T~2~ maps were generated from 14 images with echo time of 9 to 127 ms and repetition time of 2,000 ms, acquired using the multislice delay alternating with nutation for tailored excitation multiecho spin-echo (DANTE-MESE) sequence that combined black-blood preparation on the basis of nonselective DANTE pulse trains [@bib15] with chemical-shift-selective fat saturated MESE. DANTE-MESE acquired 10 slices of 2 mm thickness each, covering 2 cm of the target carotid artery, in 8 min.

Data analysis {#sec1.3}
-------------

DANTE-MESE image quality was assessed by an experienced reviewer (L.B.) who inspected the visibility of the carotid wall boundaries and rated them from 1 (poor) to 5 (excellent) according to standard procedures [@bib16]. Patients with overall quality \<3 were excluded from the study.

T~2~ maps of the carotid arteries were generated voxel by voxel using monoexponential nonlinear fitting [@bib14]; lumen and external vessel boundaries were segmented using a validated semiautomated procedure [@bib17]. As reported previously, LRNC without IPH had shorter T~2~ than normal vessel wall and fibrous tissue, whereas with recent IPH into the core, T~2~ was longer than all other plaque components [@bib14]. Therefore, to take into account the minority of plaques with recent hemorrhage into the core, segmentation used dual T~2~ thresholds, a lower one (T~2L~) indicating the maximum T~2~ value associated with lipid alone and a higher one (T~2H~) above which IPH was recorded inside the plaque lipid core. Voxels with T~2~ values below T~2L~ or above T~2H~ were thus classified as LRNC. Significant IPH (T~2~ \> T~2H~) was defined as \>5% of the total cross-sectional area. We also reported LRNC values on the basis of T~2L~ alone, taking no account of hemorrhage.

To use the data most efficiently, segmentation performance was estimated by leave-1-out cross-validation. Lipid area (%) was computed for all possible combinations of T~2L~ (range 30 to 50 ms) and T~2H~ (range 70 to 120 ms) to find the pair of threshold values that achieved the optimal lipid segmentation on T~2~ maps (i.e., the highest Pearson correlation coefficient R against lipid quantification on histology). All algorithms were implemented in Matlab (MathWorks, Natick, Massachusetts). Plaque type was also classified on the basis of T~2~ mapping and TOF data (for identification of IPH and calcium) using the modified American Heart Association (AHA) scheme [@bib10].

Histology {#sec1.4}
---------

Carotid plaques were collected at endarterectomy and divided into 2 halves at the point of maximal stenosis: one half was snap-frozen and the other half processed for paraffin embedding. Paraffin sections (5 μm) were obtained at 1-mm intervals for histological examination using hematoxylin and eosin (Sigma-Aldrich, Poole, United Kingdom) and Masson's trichrome (Merck-Millipore, Nottingham, United Kingdom), which identified collagen in the fibrous tissue (green), as well as fibrin and erythrocytes from IPH (bright red). Lipid area without previous IPH appeared transparent or unstained in both hematoxylin and eosin and Masson's trichrome stain. Stained slides were scanned using the NanoZoomer (Hamamatsu Photonics, Hamamatsu City, Japan) virtual pathology system. Frozen sections (20 μm) at the mirror plane of division on 20 randomly selected plaques were obtained for Oil Red O (Sigma-Aldrich) staining to confirm lipid presence. Because IPH occurred exclusively inside, and as part of, the LRNC, the boundary of IPH against LRNC was often impossible to define on histology ([Online Figure 1](#appsec1){ref-type="sec"}). The total histological lipid area (%) was hence calculated by combining lipid area with and without IPH. Total vessel cross-sectional area and lipid area (%) were obtained by manual segmentation using ImageJ, 64-bit, version 1.46r (National Institutes of Health, Bethesda, Maryland), as previously described [@bib18]. Plaque type was classified histologically using the AHA scheme [@bib10].

Location matching {#sec1.5}
-----------------

One investigator (L.B.) blinded to histology measured the distance from carotid bifurcation of T~2~ map locations and provided the corresponding T~1~-weighted images to a second investigator (J.T.C.) who obtained histology on the basis of the specific distance from bifurcation, and fine-tuned the exact matching location using local vessel morphology from the T~1~-weighted images provided.

Scan-rescan reproducibility {#sec1.6}
---------------------------

Scan-rescan reproducibility of lipid quantification by T~2~ mapping was studied in 10 additional patients recruited on an unselected sequential basis. They were taken out of the scanner after the first scan and left sitting for 2 min before the second scan. Both scans acquired 10 contiguous slices to cover the entire plaque and assess the reproducibility of lipid area (%) per plaque.

Statistical analysis {#sec1.7}
--------------------

All statistical analyses are reported as mean ± SEM, unless otherwise stated; Student *t* tests and chi-square tests were performed. Lipid area correlation was calculated using both slice locations and plaques as the unit of analysis. Leave-1-out cross-validation was performed on the slice-by-slice dataset of independent lipid area measurements from T~2~ maps and histology.

Results {#sec2}
=======

Patient characteristics {#sec2.1}
-----------------------

CMR scan quality ≥3 was achieved for 26 of 40 plaques, 15 symptomatic and 11 asymptomatic. Patient characteristics are summarized in [Table 1](#tbl1){ref-type="table"}. There was no significant difference between genders, major cardiovascular risk factors or medications on admission between groups.Table 1Summary of Patient Characteristics Between Symptomatic and Asymptomatic GroupsSymptomatic\
(n = 15)Asymptomatic\
(n = 11)Significance (p Value)Male:female ratio2.75:12.67:1NSAge, yrs73 (49--90)60 (43--89)0.046CV risks Hypertension14 (93.3)9 (81.8)NS Hypercholesterolemia12 (80.0)7 (63.6)NS Smoking7 (46.7)4 (36.4)NS Diabetes mellitus4 (26.7)4 (36.4)NS Previous CAD/CVA4 (26.7)6 (54.5)NSMedication at time of CEA Aspirin/antiplatelets12 (80.0)8 (72.7)NS Statins14 (93.3)10 (90.9)NS Beta-blockers4 (26.7)3 (27.3)NS Calcium antagonists5 (33.3)3 (27.3)NS ACE inhibitors/ARBs6 (40.0)5 (45.5)NS Anticoagulation3 (20.0)0 (0)NSDuplex ultrasound scan Right:left ratio6.5:11:1.20.038 Stenosis, %81.3 ± 2.584.1 ± 3.0NS[^1][^2]

AHA classification {#sec2.2}
------------------

[Figure 1](#fig1){ref-type="fig"} shows how different plaque components can be identified on T~2~ maps. To evaluate how accurately T~2~ mapping can determine plaque types, we used the modified AHA plaque classification system and compared this directly against histological classification. [Table 2](#tbl2){ref-type="table"} shows plaque types determined by T~2~ map (+ TOF) against histology, which showed good agreement (80.8%) between the 2 methods (Cohen's κ = 0.73).Figure 1Comparison of T~2~ Map, Multicontrast CMR, and HistologyT~2~ mapping identifies different components of an American Heart Association type VI plaque showing the presence of lipid **(blue)**, recent intraplaque hemorrhage (IPH) **(yellow/red)**, and calcium **(black)**. These plaque components are also visible on different weightings of multicontrast cardiovascular magnetic resonance (CMR) and are confirmed by hematoxylin and eosin (H&E) and Masson's staining on histology. Lipid was further confirmed on Oil Red O staining on adjacent frozen section. **Asterisk** indicates lumen. DAPI = 4\',6-diamidino-2-phenylindole fluorescent nuclear stains; PDW = proton density weighted; T1W = T~1~ weighted; T2W = T~2~ weighted; TOF = time-of-flight.Table 2Modified AHA Plaque Type Classification by T~2~ Mapping (+ TOF) Versus Histology Showed Good Agreement (80.8%)HistologyCMR (T2 Maps + TOF)IV to VVIVIIVIIITotalIV to V72------9VI17------8VII1---416VIII---------33Total994426[^3][^4]

Lipid quantification {#sec2.3}
--------------------

We next used T~2~ maps to quantify plaque lipid content ([Figure 2](#fig2){ref-type="fig"}). Varying according to the length of each carotid atherosclerotic lesion, an average of 2.3 slices of T~2~ map data were obtained per plaque, yielding 60 matched slices. Using leave-1-out cross-validation, the combination T~2L~ = 42 ms and T~2H~ = 90 ms produced maximum R = 0.85 (p \< 0.001) against lipid area (%) measured on histology ([Figure 3A](#fig3){ref-type="fig"}), thus achieving optimal T~2~ map segmentation for lipid quantification. Additionally, root mean square error was minimum (10.5%) and Bland-Altman analysis confirmed a high degree of agreement between T~2~ maps and histology, with only 0.03% underestimation on T~2~ maps ([Figure 3B](#fig3){ref-type="fig"}).Figure 2Quantification of Plaque LipidT~2~ and segmented map of **(A)** a plaque with large lipid-rich necrotic core (LRNC) and **(B)** a plaque with multiple smaller lipid-rich pools, and their matching histology. LRNC was segmented from the T~2~ map by thresholding (voxels with T~2~ \<42 ms or T~2~ \>90 ms). **Right panels** show 3-dimensional representations of plaque lipid distribution. Stacks of slices show lumen **(red)** and lipid **(blue contours)** segmented from T~2~ maps (for illustration). The \* signifies the lumen of the vessel. H&E = hematoxylin and eosin.Figure 3Correlation of Lipid Area Between T~2~ Mapping and Histology**(A)** Scatter plot of lipid area (%) by slice location showed excellent correlation (R = 0.85, p \< 0.001). **(B)** Bland-Altman analysis showed good agreement between histology and T~2~ map with minimal bias.

For technical validation, we made multiple comparisons of T~2~ maps and tissue stains per slice. However, for biological applications, the unit of analysis would be per plaque rather than per slice. Grouping individual slice locations from each plaque on the same scatter plot, we showed that data points from the same plaque were relatively closely clustered together ([Figure 4A](#fig4){ref-type="fig"}), indicating that slices from the same plaque tend to contain similar proportions of lipid. Furthermore, comparing the average lipid area (%) per plaque measured by T~2~ map and by histology maintained a strong correlation (R = 0.83, p \< 0.001) ([Figure 4B](#fig4){ref-type="fig"}).Figure 4Plaque-by-Plaque Correlation of Lipid Area**(A)** Scatter plot of lipid area (%) to show slices from the same plaque (individually colored, see legend) tend to contain similar proportions of lipid. **(B)** Strong correlation maintained with plaque-by-plaque comparison (R = 0.83, p \< 0.001). \*\*\*p \< 0.001.

Symptomatic versus asymptomatic {#sec2.4}
-------------------------------

We then tested using T~2~ mapping whether LRNC size varied between different clinical presentations. Symptomatic plaques were found to have significantly higher lipid area (%), compared to asymptomatic plaques (31.5 ± 3.7% vs. 15.8 ± 3.1%; p = 0.005, relative difference 99.4%) ([Figure 5A](#fig5){ref-type="fig"}). This was despite similar degree of carotid stenosis (81.3 ± 2.5% symptomatic vs. 84.1 ± 3.0% asymptomatic; p = NS), and only a modest difference in terms of plaque volume (128.0 ± 6.0 mm^3^ symptomatic vs. 105.6 ± 9.4 mm^3^ asymptomatic; p = 0.04; relative difference = 21.2%). In addition, using an established definition of large LRNC as ≥25% of cross-sectional area [@bib3], [@bib19], we further confirmed that symptomatic plaques had significantly larger LRNC using T~2~ mapping alone (p = 0.003) ([Figure 5B](#fig5){ref-type="fig"}). Finally, the receiver-operating characteristic (ROC) area under the curve was 0.79 (p = 0.01), indicating that lipid quantification by T~2~ mapping has a good ability to discriminate between symptomatic and asymptomatic plaques in our clinical cohorts. ROC analysis determined the optimal cutoff for LRNC between clinical cohorts to be ∼25% (sensitivity = 67%, specificity = 91%) ([Figure 5C](#fig5){ref-type="fig"}).Figure 5Symptomatic Plaques Contain More Lipid Than Asymptomatic Plaques**(A)** Symptomatic plaques contained significant more lipid than asymptomatic plaques (31.5 ± 3.7% vs. 15.8 ± 3.1%; p = 0.005) despite similar degree of luminal stenosis. **(B)** Chi-square test using an established cutoff of \>25% to define a large lipid-rich necrotic core (LRNC) showed similar results. **(C)** Receiver-operating characteristic curve analysis showed that T~2~ mapping has a fair to good ability to discriminate between symptomatic and asymptomatic plaques. ∗p \< 0.05, ∗∗p \< 0.01. AUC = area under the curve.

Intraplaque hemorrhage {#sec2.5}
----------------------

To clarify whether the inclusion of IPH in our calculation with a second T~2~ threshold had influenced our results, we examined the prevalence of IPH and its contribution to the total lipid area (%). Sixteen of the total 60 slices contained significant (\>5%) IPH. Of these, only 7 had IPH infiltrating \>50% of the lipid core. Thus IPH made a relatively minor contribution to the total lipid measurement. [Figure 6](#fig6){ref-type="fig"} shows the copresence of IPH and lipid-filled macrophage foam cells. We then reanalyzed our data using a single T~2~ threshold of \<42 ms for segmentation and lipid area calculation, by so doing effectively excluded IPH (long T~2~) as part of the LRNC in T~2~ map segmentation, yet the strength of correlation was similar to our dual T~2~ threshold approach (R = 0.79 vs. 0.85). In fact, if we excluded those 7 slices with large (\>50%) IPH from the cohort, the correlation of the remaining 53 slices using a single threshold (\<42 ms) approach went back to R = 0.85.Figure 6IPH Is Structurally Integral to the LRNC**(A)** Large intraplaque hemorrhage (IPH) in background lipid-rich necrotic core (LRNC). Erythrocytes and fibrin staining on Masson's trichrome confirmed IPH. Copresence of macrophage and lipid droplets confirmed by immunohistochemistry against cluster of differentiation 68 (CD68) and adipophilin [@bib35]. **(B)** Small IPH areas, structurally continuous with background LRNC, detected by T~2~ mapping and histology. Note: a small area of fresh blood at the specimen border seen at 12 o'clock position is a surgical artifact. H&E = hematoxylin and eosin.

Scan-rescan reproducibility {#sec2.6}
---------------------------

One of the 10 carotid plaques scanned to evaluate reproducibility was rejected due to low image quality during rescan. For the remaining 9 plaques, lipid core measurements ranged from 5.7% to 36.6% with a mean of 20.3%. The scan-rescan reproducibility was excellent (intraclass correlation coefficient = 0.89; 95% confidence interval: 0.59 to 0.98; coefficient of variation = 8.9% \[plaque-by-plaque comparison\]).

Discussion {#sec3}
==========

This work makes 2 principal findings. First, in vivo T~2~ mapping, on a voxel-by-voxel basis, and at high resolution, enables accurate and highly reproducible quantification of plaque lipid, validated with histology. Second, lipid quantification by T~2~ mapping can distinguish recently symptomatic plaques with high sensitivity and specificity.

Deposition and retention of cholesterol-rich lipoproteins is a cardinal feature of atherosclerosis, occurring from the earliest foam cell lesions through to the complex plaques of advanced disease. Where the rate of deposition exceeds the rate of clearance, cholesterol and cholesterol derivatives can accumulate within the plaque. The presence of a large LRNC (especially associated with a thin overlying fibrous cap) has been associated with high risk of rupture and atherothrombotic complications [@bib3]. Furthermore, the presence of lipid in the plaque is a driver of local inflammation [@bib20] and altered gene expression [@bib21]. Because of these central roles, quantification of plaque lipid has been a key aim of various atherosclerosis imaging techniques such as intravascular ultrasound [@bib22], near infrared spectroscopy [@bib23], cardiac computed tomography [@bib24], and vascular magnetic resonance imaging [@bib11].

Since the first description of Toussaint et al. [@bib25], magnetic resonance techniques have been applied for the detection of LRNC [@bib26], [@bib27]. However, a significant limitation of this approach is low sensitivity, such that LRNC can be detected only in a minority of plaques with relatively large coalesced lipid pools. In a survey of 100 patients with varying extents of coronary atheroma, only 20% had a discernable LRNC in the carotid artery on multicontrast CMR [@bib28]. Reliable detection of small scattered pools of lipid depends on image resolution and signal-to-noise ratio in both T~2~ mapping and multicontrast CMR. The main advantage of T~2~ mapping is to provide quantitative information, on a per-voxel basis, using direct measurement of an absolute physical property of plaque components. Our approach to lipid quantification is therefore more objective and less dependent on acquisition parameters than multicontrast CMR, which relies on relative signal intensities for plaque segmentation. In addition, T~2~ mapping does not suffer from blurring artifacts intrinsic to fast spin echo acquisition [@bib12], nor does it require image coregistration and intensity correction [@bib13]. Finally, it is more time efficient (one-fifth of the time required by multicontrast protocol for LRNC quantification) [@bib6], [@bib11] and without exposing patients to a gadolinium-based contrast agent. Because the validation required tissue obtained by endarterectomy (undertaken for severe stenotic disease), our series contains relatively large lesions (of AHA classes IV to VIII on histology). In this context, plaque lipid was detectable in virtually all cases.

Atherosclerosis regression is a term used to denote favorable remodeling of plaque, for instance in response to aggressive reduction in plasma level of atherogenic lipoproteins [@bib29]. Normalization of plasma lipid profile in genetically modified hyperlipidemic mice with atherosclerosis leads to marked loss of plaque lipid and deposition of fibrous tissue [@bib7], with similar changes inferred in man [@bib30]. This has important implications in the clinic because some antiatherosclerotic agents may well change plaque lipid content, without necessarily altering total plaque volume. This suggests that accurate quantification of plaque lipid might prove useful for patient stratification and selection for intensive lipid lowering therapies or monitoring of response to treatment, including in clinical trials. The technique validated here shows excellent scan-rescan reproducibility and would be well suited to serial application in lipid-intervention trials. This may be important since several new classes of lipid lowering therapies have been developed, including lipoprotein(a) and apolipoprotein B antisense, microsomal triglyceride transfer protein inhibition, cholesteryl ester transfer protein inhibitors, and proprotein convertase subtilisin/kexin type 9 inhibitors, but considerations of cost effectiveness, mode of administration, and, in some cases, potential toxicity mean that they are unlikely to be used indiscriminately in patients with atherosclerotic disease. Methods for rational stratification are therefore needed.

Applying T~2~ mapping in our different clinical cohorts, we found that despite having similar degree of carotid stenosis, and only a modest 21.2% difference in terms of plaque volume, symptomatic plaques had 99.4% larger LRNC than asymptomatic plaques. ROC analysis confirmed our technique having good ability to distinguish between symptomatic and asymptomatic plaques with optimal LRNC cutoff at 25% of the cross-sectional area, in agreement with large-scale histological series in both carotid [@bib3] and coronary [@bib31] locations. The ability to accurately quantify plaque lipid might also prove useful in informing decisions between carotid surgery and stenting because a large LRNC is considered to be an important factor determining the amount of stent-related downstream debris [@bib32] and has been shown to increase risk of stroke following carotid stenting [@bib32], [@bib33]. Three-dimensional rendering of lipid distribution in relation to local vessel anatomy using quantitative T~2~ mapping data may assist interventional procedural planning to minimize such risks ([Figure 2](#fig2){ref-type="fig"}, right panels).

Study limitations {#sec3.1}
-----------------

The main limitation of our method is the sensitivity to motion artifacts, a fact reflected in the scan rejection rate (35%), which is comparable to that of multicontrast CMR (30%) [@bib11]. Strategies for motion correction are currently being actively pursued. Another limitation is the challenge to measure IPH independently, mainly because of the tendency for hemorrhage to be mixed with LRNC. Moreover, as IPH ages and organizes, not only do its magnetic resonance properties change [@bib16], but also its histological appearance, as organization replaces fibrin with a more collagen-like extracellular matrix structure [@bib34]. We therefore analyzed our data using 2 approaches: 1 with dual T~2~ thresholds that included both lipid and IPH and another with a single T~2~ threshold to effectively exclude IPH as part of the LRNC measurement. By either method, the strength of correlation was similar (R = 0.79 vs. 0.85). This demonstrated empirically that T~2~ mapping does track plaque lipid content accurately, whether or not IPH is considered as part of the LRNC calculation. Finally, this histological validation study has a relatively small number of subjects and CMR slices. To utilize the available data most efficiently, we employed leave-1-out cross-validation to test the performance of our T~2~ segmentation model on data that were not used to build it.

Conclusions {#sec4}
===========

We provided histological validation of a new in vivo multislice T~2~ mapping technique for quantification of plaque lipid content. Not only can T~2~ mapping distinguish between symptomatic and asymptomatic plaques on the basis of their lipid content, but we showed that despite similar degree of luminal stenosis and only modest difference in plaque volume, symptomatic plaques contained nearly double the lipid content compared with asymptomatic plaques on T~2~ maps. This technique may be of value in patient selection and evaluating response to new antiatherosclerotic treatment and interventions.Perspectives**COMPETENCY IN MEDICAL KNOWLEDGE:** Quantitative T~2~ mapping is a novel technique in characterization of carotid atherosclerotic plaques. Using histological validation, this study demonstrated its ability to differentiate various plaque components, with an emphasis on lipid quantification. Symptom-related plaques were shown to contain significantly more lipid despite similar degree of luminal stenosis and only modest difference in plaque volume compared with asymptomatic plaques. T~2~ mapping is accurate and reproducible; it is an alternative technique to the conventional multicontrast approach, which may be of value in future lipid intervention trials and cardiovascular risk stratification.**TRANSLATIONAL OUTLOOK:** Technical improvements are actively pursued, to reduce imaging time by compressed sensing, increase spatial resolution coverage and signal-to-noise ratios by better multichannel coils, and reduce motion artifacts by the development of image navigator--based approaches. How the changes in the size of lipid-rich core in vulnerable plaques, as an imaging biomarker, translate to the modification of cardiovascular risks remain to be elucidated.

Appendix {#appsec1}
========
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[^1]: Values are median (range), n (%), or mean ± SEM.

[^2]: ACE = angiotensin-converting enzyme; ARB = angiotensin receptor blocker; CAD = coronary artery disease; CEA = carotid endarterectomy; CV = cardiovascular; CVA = cerebrovascular accident; NS = not significant.

[^3]: Cohen's κ = 0.73.

[^4]: AHA = American Heart Association; CMR = cardiovascular magnetic resonance; TOF = time-of-flight.
